189 related articles for article (PubMed ID: 31840131)
1. Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification.
Ikegaki N; Shimada H;
JCO Precis Oncol; 2019; 3():. PubMed ID: 31840131
[No Abstract] [Full Text] [Related]
2. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
[TBL] [Abstract][Full Text] [Related]
3. Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
Kim JW; Park SH; Choi SA; Kim SK; Koh EJ; Won JK; Nam SM; Phi JH
BMC Cancer; 2022 Nov; 22(1):1221. PubMed ID: 36437460
[TBL] [Abstract][Full Text] [Related]
4. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
5. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
[TBL] [Abstract][Full Text] [Related]
6. High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.
Ramani P; Sowa-Avugrah E; May MT
Virchows Arch; 2015 Sep; 467(3):319-27. PubMed ID: 26199132
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Dungwa JV; Hunt LP; Ramani P
Hum Pathol; 2012 Oct; 43(10):1651-60. PubMed ID: 22436629
[TBL] [Abstract][Full Text] [Related]
10. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening.
Kusafuka T; Nagahara N; Oue T; Imura K; Nakamura T; Kobayashi Y; Komoto Y; Fukuzawa M; Okada A; Nakayama M
Cancer; 1995 Aug; 76(4):695-9. PubMed ID: 8625168
[TBL] [Abstract][Full Text] [Related]
11. Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan.
Suita S; Tajiri T; Higashi M; Tanaka S; Kinoshita Y; Takahashi Y; Tatsuta K
Eur J Pediatr Surg; 2007 Feb; 17(1):23-8. PubMed ID: 17407017
[TBL] [Abstract][Full Text] [Related]
12. Histologic and immunohistochemical investigation of neuroblastomas and correlation with prognosis.
Brook FB; Raafat F; Eldeeb BB; Mann JR
Hum Pathol; 1988 Aug; 19(8):879-88. PubMed ID: 2969864
[TBL] [Abstract][Full Text] [Related]
13. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma.
Cohn SL; Rademaker AW; Salwen HR; Franklin WA; Gonzales-Crussi F; Rosen ST; Bauer KD
Am J Pathol; 1990 May; 136(5):1043-52. PubMed ID: 2349963
[TBL] [Abstract][Full Text] [Related]
14. One hundred neuroblastomas detected through a mass screening system in Japan.
Hachitanda Y; Ishimoto K; Hata J; Shimada H
Cancer; 1994 Dec; 74(12):3223-6. PubMed ID: 7982186
[TBL] [Abstract][Full Text] [Related]
15. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and immunohistochemical analysis of an adult anaplastic neuroblastoma.
Cowan JM; Dayal Y; Schwaitzberg S; Tischler AS
Am J Surg Pathol; 1997 Aug; 21(8):957-63. PubMed ID: 9255260
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine in complex diseases-Molecular subgrouping for improved prediction and treatment stratification.
Johansson Å; Andreassen OA; Brunak S; Franks PW; Hedman H; Loos RJF; Meder B; Melén E; Wheelock CE; Jacobsson B
J Intern Med; 2023 Oct; 294(4):378-396. PubMed ID: 37093654
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic and immunohistochemical features of neuroblastoma: a tool for evaluating prognosis.
Bigotti G; Coli A
Tumori; 1990 Aug; 76(4):374-8. PubMed ID: 2399568
[TBL] [Abstract][Full Text] [Related]
19. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
20. Growth patterns of human neuroblastoma xenografts and their relationship to treatment outcome.
George BA; Yanik G; Wells RJ; Martin LW; Soukup S; Ballard ET; Gartside PS; Lampkin BC
Cancer; 1993 Dec; 72(11):3331-9. PubMed ID: 8242560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
